Albumin therapy for hepatic encephalopathy: current evidence and controversies

AbstractHepatic encephalopathy (HE) is a common complication that occurs in 16 –21% of end-stage cirrhosis patients. Emerging evidence suggests that systemic inflammation and oxidative stress may play a role in the development of HE. Recent understanding on the anti-inflammatory properties of human albumin has led to growing interest of using human albumin for the treatment and prevention of HE among decompensated patients. In this review, we aim to discuss the current evidence and controversies of using human albumin for the treatment and prevention of HE in advanced cirrhosis patients.

Source: Metabolic Brain Disease - May 15, 2023 Category: Neurology Source Type: research